Cargando…
Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic prevalence between 1:400 and 1:1,000 individuals, is the third most common cause of end stage kidney disease after diabetes mellitus and hypertension. Over the last 3 decades there has been great progress in understandin...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478168/ https://www.ncbi.nlm.nih.gov/pubmed/36120538 http://dx.doi.org/10.3389/fmolb.2022.981963 |